Stockreport

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Cognition Therapeutics, Inc.  (CGTX) 
PDF PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates [Read more]